VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Luke on Impactful Data in the Field of Melanoma

Jason Luke, MD
Published: Monday, Oct 09, 2017



Jason Luke, MD, an assistant professor of medicine at the University of Chicago Medicine, discusses impactful data in the field of melanoma.

According to Luke, the most impactful data are in the setting of adjuvant therapy after surgery. The BRIM8 trial is investigating vemurafenib (Zelboraf) versus placebo, the COMBI-AD study is investigating dabrafenib (Tafinlar) and trametinib (Mekinist) versus placebo, and the CheckMate-238 study is investigating nivolumab (Opdivo) versus ipilimumab (Yervoy).

All of these data sets are reading out as positive and showing improvements in relapse-free survival. Longer follow-up in terms of overall survival are still needed.


Jason Luke, MD, an assistant professor of medicine at the University of Chicago Medicine, discusses impactful data in the field of melanoma.

According to Luke, the most impactful data are in the setting of adjuvant therapy after surgery. The BRIM8 trial is investigating vemurafenib (Zelboraf) versus placebo, the COMBI-AD study is investigating dabrafenib (Tafinlar) and trametinib (Mekinist) versus placebo, and the CheckMate-238 study is investigating nivolumab (Opdivo) versus ipilimumab (Yervoy).

All of these data sets are reading out as positive and showing improvements in relapse-free survival. Longer follow-up in terms of overall survival are still needed.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x